Tempus AI (NASDAQ:TEM) Director David Epstein Sells 370 Shares of Stock

Tempus AI, Inc. (NASDAQ:TEM) Director David Epstein sold 370 shares of Tempus AI stock in a transaction on Monday, November 2nd. The stock was sold at an average price of $74.29, for a total transaction of $27,487.30. Following the sale, the director owned 30,474 shares in the company, valued at $2,263,913.46. This represents a 1.20% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Tempus AI Stock Performance

NASDAQ:TEM traded down $2.19 during mid-day trading on Wednesday, reaching $75.61. 5,914,520 shares of the stock were exchanged, compared to its average volume of 6,242,277. The stock has a market capitalization of $13.64 billion, a P/E ratio of -71.33 and a beta of 3.61. Tempus AI, Inc. has a 1 year low of $40.77 and a 1 year high of $89.09. The company has a 50 day simple moving average of $71.04 and a 200-day simple moving average of $57.17. The company has a quick ratio of 3.16, a current ratio of 3.30 and a debt-to-equity ratio of 3.06.

Tempus AI (NASDAQ:TEM) last announced its earnings results on Monday, November 2nd. The company reported $0.07 EPS for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.16. Tempus AI had a negative net margin of 12.54% and a negative return on equity of 48.29%. The business had revenue of $411.54 million during the quarter, compared to analysts’ expectations of $409.39 million. During the same period in the prior year, the company earned ($0.46) earnings per share. The business’s revenue was up 23.1% compared to the same quarter last year. Analysts anticipate that Tempus AI, Inc. will post -1.45 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in TEM. Sumitomo Mitsui Trust Group Inc. lifted its position in Tempus AI by 23.4% during the first quarter. Sumitomo Mitsui Trust Group Inc. now owns 4,326,313 shares of the company’s stock valued at $195,636,000 after buying an additional 821,490 shares in the last quarter. Amova Asset Management Americas Inc. grew its stake in Tempus AI by 23.4% during the first quarter. Amova Asset Management Americas Inc. now owns 4,326,313 shares of the company’s stock worth $195,549,000 after buying an additional 821,490 shares during the period. Pictet Asset Management Holding SA increased its position in shares of Tempus AI by 2,965.7% in the third quarter. Pictet Asset Management Holding SA now owns 502,897 shares of the company’s stock worth $41,233,000 after acquiring an additional 486,493 shares in the last quarter. Eagle Health Investments LP acquired a new stake in shares of Tempus AI in the first quarter worth $11,588,000. Finally, Swiss National Bank raised its stake in shares of Tempus AI by 0.3% in the 1st quarter. Swiss National Bank now owns 183,500 shares of the company’s stock valued at $8,298,000 after acquiring an additional 600 shares during the period. Hedge funds and other institutional investors own 24.22% of the company’s stock.

Trending Headlines about Tempus AI

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: Tempus reported Q3 revenue of $411.5 million, up 23.1% year over year, and earnings of $0.07 per share—above expectations for a loss. The company raised its 2026 revenue outlook to $1.60–$1.605 billion and outlined a $65 million adjusted EBITDA target. Tempus Q3 results
• Positive Sentiment: Management cited oncology demand, expanding data partnerships and reimbursement-related pricing gains as growth drivers, including potential pricing upside in 2027. Q3 earnings call highlights
• Positive Sentiment: Several analysts raised price targets after the results: HC Wainwright to $85, and Robert W. Baird and Cantor Fitzgerald to $92. Needham also said the shares were expected to rise. Analysts boost forecasts
• Positive Sentiment: Tempus shares also benefited from strength in AI stocks at the U.S. market open, adding to the positive earnings-driven momentum. AI stocks rise at market open
• Negative Sentiment: Some coverage cautioned that the stock may be fully valued after a sharp recent run and flagged cash-burn concerns. UBS maintained a Hold rating, citing weaker hereditary testing alongside stronger oncology performance. Valuation concerns
• Negative Sentiment: Analysts have also highlighted potential integration challenges related to Tempus’s proposed Personalis acquisition, which could weigh on execution and future performance. Personalis integration risks

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the stock. Stifel Nicolaus reduced their price target on shares of Tempus AI from $60.00 to $50.00 and set a “hold” rating for the company in a research report on Monday, August 3rd. Roth Capital began coverage on Tempus AI in a research note on Tuesday, September 8th. They issued a “neutral” rating and a $67.00 price objective for the company. Guggenheim lifted their price objective on Tempus AI from $65.00 to $92.00 and gave the stock a “buy” rating in a report on Thursday, October 1st. Piper Sandler upgraded Tempus AI from a “neutral” rating to an “overweight” rating and boosted their target price for the stock from $56.00 to $76.00 in a research report on Tuesday, September 1st. Finally, UBS Group initiated coverage on Tempus AI in a report on Wednesday, September 9th. They issued a “neutral” rating and a $70.00 target price on the stock. Eleven analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $79.37.

Tempus AI Company Profile

Tempus AI, Inc is a healthcare technology company that uses artificial intelligence and data analytics to support precision medicine. The company combines clinical, molecular and imaging data to help physicians make more informed treatment decisions and to help researchers and biopharmaceutical companies develop therapies.

Its offerings include genomic testing and analysis, such as tissue- and blood-based tests, as well as software tools designed to assist with clinical decision-making, patient matching for clinical trials and the management of healthcare data.